Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis

*School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China; and

†Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.

Correspondence: Sigui Zhou, PhD, School of Pharmacy, GuangDong Pharmaceutical University (Higher Education Mega Center), 280 East Wai-huan Rd., Guangzhou, China 510006 (e-mail: [email protected]).

Supported by the National Natural Science Foundation of China (No. 81670239), Special project in key fields of normal university in Guangdong Province (No. 2021ZDZX2019), National Key Clinical Specialty Construction Project (Clinical Pharmacy) and High-Level Clinical Key Specialty (Clinical Pharmacy) in Guangdong Province.

The authors report no conflicts of interest.

S. Zhou designed and supervised the study and revised the paper. Z. Shu and J. Feng performed the experiments and wrote the paper. L. Liu, Y. Liao, Y. Cao, Z. Zeng, Q. Huang, and Zhonghong Li performed the experiments. G. Jin, Z. Yang, and J. Xing analyzed the data. All authors read and approved the final manuscript.

The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Guangdong Pharmaceutical University (medical ethics approval [2021] No. 103 and [2019] No. 77).

Z. Shu and J. Feng have contributed equally to this work.

留言 (0)

沒有登入
gif